TriangleNCT02815995 · OUTCOME
Tumor Response
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- COUNT_OF_PARTICIPANTS
- Unit
- Participants
- Interval / dispersion
- Not reported
- Time frame
- 8 weeks, confirmatory scan at least 4 wks or later
What was measured
Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR),Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR
Groups in this outcome
Adipocytic Tumors Group
Adipocytic Tumors Group consists of well-diff/de-differentiated, pleomorphic and myxoid LPS. Age group ≥12 and \<18: Dosages of study drugs to be determined (TBD). Age group ≥ 18: Durvalumab 1500 mg and Tremelimumab 75 mg every 4 weeks for 4 cycles followed by durvalumab 1500 mg every 4 weeks for up to 8 additional cycles. Combination of both agents administered every 4 weeks for a maximum of 4 doses, after which durvalumab continues as a single agent every 4 weeks till progression or unacceptable toxicity for a maximum of 8 additional doses. Durvalumab: Age group ≥ 18: Durvalumab 1500 mg by vein every 4 weeks for 4 cycles. After Week 16, participant may continue to receive durvalumab alone by vein for an additional 32 weeks (8 doses). Tremelimumab: Age group ≥ 18: Tremelimumab 75 mg every 4 weeks for 4 cycles.
Vascular Tumors Group
Vascular Tumors Group consists of leiomyosarcomas, angiosarcomas, epithelioid hemangioendotheliomas, and hemangiopericytomas. Age group ≥12 and \<18: Dosages of study drugs to be determined (TBD). Age group ≥ 18: Durvalumab1500 mg and Tremelimumab 75 mg every 4 weeks for 4 cycles followed by Durvalumab 1500 mg every 4 weeks for up to 8 additional cycles. Combination of both agents administered every 4 weeks for a maximum of 4 doses, after which durvalumab continues as a single agent every 4 weeks till progression or unacceptable toxicity for a maximum of 8 additional doses. Durvalumab: Age group ≥ 18: Durvalumab 1500 mg by vein every 4 weeks for 4 cycles. After Week 16, participant may continue to receive durvalumab alone by vein for an additional 32 weeks (8 doses). Tremelimumab: Age group ≥ 18: Tremelimumab 75 mg every 4 weeks for 4 cycles.
Undifferentiated Pleomorphic Sarcoma Group
Age group ≥12 and \<18: Dosages of study drugs to be determined (TBD). Age group ≥ 18: Durvalumab 1500 mg and Tremelimumab 75 mg every 4 weeks for 4 cycles followed by Durvalumab 1500 mg every 4 weeks for up to 8 additional cycles. Combination of both agents administered every 4 weeks for a maximum of 4 doses, after which durvalumab continues as a single agent every 4 weeks till progression or unacceptable toxicity for a maximum of 8 additional doses. Durvalumab: Age group ≥ 18: Durvalumab 1500 mg by vein every 4 weeks for 4 cycles. After Week 16, participant may continue to receive durvalumab alone by vein for an additional 32 weeks (8 doses). Tremelimumab: Age group ≥ 18: Tremelimumab 75 mg every 4 weeks for 4 cycles.
Synovial Sarcoma Group
Age group ≥12 and \<18: Dosages of study drugs to be determined (TBD). Age group ≥ 18: Durvalumab 1500 mg and Tremelimumab 75 mg every 4 weeks for 4 cycles followed by durvalumab 1500 mg every 4 weeks for up to 8 additional cycles. Combination of both agents administered every 4 weeks for a maximum of 4 doses, after which Durvalumab continues as a single agent every 4 weeks till progression or unacceptable toxicity for a maximum of 8 additional doses. Durvalumab: Age group ≥ 18: Durvalumab 1500 mg by vein every 4 weeks for 4 cycles. After Week 16, participant may continue to receive durvalumab alone by vein for an additional 32 weeks (8 doses). Tremelimumab: Age group ≥ 18: Tremelimumab 75 mg every 4 weeks for 4 cycles.
Osteosarcoma Group
Age group ≥12 and \<18: Dosages of study drugs to be determined (TBD). Age group ≥ 18: Durvalumab 1500 mg and Tremelimumab 75 mg every 4 weeks for 4 cycles followed by durvalumab 1500 mg every 4 weeks for up to 8 additional cycles. Combination of both agents administered every 4 weeks for a maximum of 4 doses, after which Durvalumab continues as a single agent every 4 weeks till progression or unacceptable toxicity for a maximum of 8 additional doses. Durvalumab: Age group ≥ 18: Durvalumab 1500 mg by vein every 4 weeks for 4 cycles. After Week 16, participant may continue to receive durvalumab alone by vein for an additional 32 weeks (8 doses). Tremelimumab: Age group ≥ 18: Tremelimumab 75 mg every 4 weeks for 4 cycles.
Other Sarcomas Group
Age group ≥12 and \<18: Dosages of study drugs to be determined (TBD). Age group ≥ 18: Durvalumab 1500 mg and Tremelimumab 75 mg every 4 weeks for 4 cycles followed by durvalumab 1500 mg every 4 weeks for up to 8 additional cycles. Combination of both agents administered every 4 weeks for a maximum of 4 doses, after which Durvalumab continues as a single agent every 4 weeks till progression or unacceptable toxicity for a maximum of 8 additional doses. Durvalumab: Age group ≥ 18: Durvalumab 1500 mg by vein every 4 weeks for 4 cycles. After Week 16, participant may continue to receive durvalumab alone by vein for an additional 32 weeks (8 doses). Tremelimumab: Age group ≥ 18: Tremelimumab 75 mg every 4 weeks for 4 cycles.
Alveolar Soft-part Sarcoma Group
Age group ≥12 and \<18: Dosages of study drugs to be determined (TBD). Age group ≥ 18: Durvalumab 1500 mg and Tremelimumab 75 mg every 4 weeks for 4 cycles followed by durvalumab 1500 mg every 4 weeks for up to 8 additional cycles. Combination of both agents administered every 4 weeks for a maximum of 4 doses, after which Durvalumab continues as a single agent every 4 weeks till progression or unacceptable toxicity for a maximum of 8 additional doses. Durvalumab: Age group ≥ 18: Durvalumab 1500 mg by vein every 4 weeks for 4 cycles. After Week 16, participant may continue to receive durvalumab alone by vein for an additional 32 weeks (8 doses). Tremelimumab: Age group ≥ 18: Tremelimumab 75 mg every 4 weeks for 4 cycles.
Chordomas Group
Age group ≥12 and \<18: Dosages of study drugs to be determined (TBD). Age group ≥ 18: Durvalumab 1500 mg and Tremelimumab 75 mg every 4 weeks for 4 cycles followed by durvalumab 1500 mg every 4 weeks for up to 8 additional cycles. Combination of both agents administered every 4 weeks for a maximum of 4 doses, after which Durvalumab continues as a single agent every 4 weeks till progression or unacceptable toxicity for a maximum of 8 additional doses. Durvalumab: Age group ≥ 18: Durvalumab 1500 mg by vein every 4 weeks for 4 cycles. After Week 16, participant may continue to receive durvalumab alone by vein for an additional 32 weeks (8 doses). Tremelimumab: Age group ≥ 18: Tremelimumab 75 mg every 4 weeks for 4 cycles.
| Group | Source count |
|---|---|
| Adipocytic Tumors Group | 6 |
| Vascular Tumors Group | 10 |
| Undifferentiated Pleomorphic Sarcoma Group | 5 |
| Synovial Sarcoma Group | 5 |
| Osteosarcoma Group | 5 |
| Other Sarcomas Group | 11 |
| Alveolar Soft-part Sarcoma Group | 10 |
| Chordomas Group | 5 |
Reported measurements
Best Response irRC - N/A
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Adipocytic Tumors Group | 0 | Not reported | Not reported | Not reported | Not reported |
| Vascular Tumors Group | 0 | Not reported | Not reported | Not reported | Not reported |
| Undifferentiated Pleomorphic Sarcoma Group | 0 | Not reported | Not reported | Not reported | Not reported |
| Synovial Sarcoma Group | 0 | Not reported | Not reported | Not reported | Not reported |
| Osteosarcoma Group | 1 | Not reported | Not reported | Not reported | Not reported |
| Other Sarcomas Group | 0 | Not reported | Not reported | Not reported | Not reported |
| Alveolar Soft-part Sarcoma Group | 0 | Not reported | Not reported | Not reported | Not reported |
| Chordomas Group | 0 | Not reported | Not reported | Not reported | Not reported |
Best Response irRC - PD
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Adipocytic Tumors Group | 3 | Not reported | Not reported | Not reported | Not reported |
| Vascular Tumors Group | 7 | Not reported | Not reported | Not reported | Not reported |
| Undifferentiated Pleomorphic Sarcoma Group | 2 | Not reported | Not reported | Not reported | Not reported |
| Synovial Sarcoma Group | 1 | Not reported | Not reported | Not reported | Not reported |
| Osteosarcoma Group | 3 | Not reported | Not reported | Not reported | Not reported |
| Other Sarcomas Group | 5 | Not reported | Not reported | Not reported | Not reported |
| Alveolar Soft-part Sarcoma Group | 1 | Not reported | Not reported | Not reported | Not reported |
| Chordomas Group | 1 | Not reported | Not reported | Not reported | Not reported |
Best Response irRC - PR
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Adipocytic Tumors Group | 0 | Not reported | Not reported | Not reported | Not reported |
| Vascular Tumors Group | 1 | Not reported | Not reported | Not reported | Not reported |
| Undifferentiated Pleomorphic Sarcoma Group | 1 | Not reported | Not reported | Not reported | Not reported |
| Synovial Sarcoma Group | 0 | Not reported | Not reported | Not reported | Not reported |
| Osteosarcoma Group | 0 | Not reported | Not reported | Not reported | Not reported |
| Other Sarcomas Group | 0 | Not reported | Not reported | Not reported | Not reported |
| Alveolar Soft-part Sarcoma Group | 5 | Not reported | Not reported | Not reported | Not reported |
| Chordomas Group | 1 | Not reported | Not reported | Not reported | Not reported |
Best Response irRC - SD
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Adipocytic Tumors Group | 3 | Not reported | Not reported | Not reported | Not reported |
| Vascular Tumors Group | 1 | Not reported | Not reported | Not reported | Not reported |
| Undifferentiated Pleomorphic Sarcoma Group | 1 | Not reported | Not reported | Not reported | Not reported |
| Synovial Sarcoma Group | 2 | Not reported | Not reported | Not reported | Not reported |
| Osteosarcoma Group | 1 | Not reported | Not reported | Not reported | Not reported |
| Other Sarcomas Group | 3 | Not reported | Not reported | Not reported | Not reported |
| Alveolar Soft-part Sarcoma Group | 4 | Not reported | Not reported | Not reported | Not reported |
| Chordomas Group | 3 | Not reported | Not reported | Not reported | Not reported |
Best Response irRC - uPD
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Adipocytic Tumors Group | 0 | Not reported | Not reported | Not reported | Not reported |
| Vascular Tumors Group | 1 | Not reported | Not reported | Not reported | Not reported |
| Undifferentiated Pleomorphic Sarcoma Group | 1 | Not reported | Not reported | Not reported | Not reported |
| Synovial Sarcoma Group | 2 | Not reported | Not reported | Not reported | Not reported |
| Osteosarcoma Group | 0 | Not reported | Not reported | Not reported | Not reported |
| Other Sarcomas Group | 3 | Not reported | Not reported | Not reported | Not reported |
| Alveolar Soft-part Sarcoma Group | 0 | Not reported | Not reported | Not reported | Not reported |
| Chordomas Group | 0 | Not reported | Not reported | Not reported | Not reported |
Best Response iRecist - N/A
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Adipocytic Tumors Group | 0 | Not reported | Not reported | Not reported | Not reported |
| Vascular Tumors Group | 0 | Not reported | Not reported | Not reported | Not reported |
| Undifferentiated Pleomorphic Sarcoma Group | 0 | Not reported | Not reported | Not reported | Not reported |
| Synovial Sarcoma Group | 0 | Not reported | Not reported | Not reported | Not reported |
| Osteosarcoma Group | 1 | Not reported | Not reported | Not reported | Not reported |
| Other Sarcomas Group | 0 | Not reported | Not reported | Not reported | Not reported |
| Alveolar Soft-part Sarcoma Group | 0 | Not reported | Not reported | Not reported | Not reported |
| Chordomas Group | 0 | Not reported | Not reported | Not reported | Not reported |
Best Response iRecist - PD
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Adipocytic Tumors Group | 3 | Not reported | Not reported | Not reported | Not reported |
| Vascular Tumors Group | 7 | Not reported | Not reported | Not reported | Not reported |
| Undifferentiated Pleomorphic Sarcoma Group | 2 | Not reported | Not reported | Not reported | Not reported |
| Synovial Sarcoma Group | 0 | Not reported | Not reported | Not reported | Not reported |
| Osteosarcoma Group | 3 | Not reported | Not reported | Not reported | Not reported |
| Other Sarcomas Group | 5 | Not reported | Not reported | Not reported | Not reported |
| Alveolar Soft-part Sarcoma Group | 1 | Not reported | Not reported | Not reported | Not reported |
| Chordomas Group | 1 | Not reported | Not reported | Not reported | Not reported |
Best Response iRecist - PR
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Adipocytic Tumors Group | 0 | Not reported | Not reported | Not reported | Not reported |
| Vascular Tumors Group | 1 | Not reported | Not reported | Not reported | Not reported |
| Undifferentiated Pleomorphic Sarcoma Group | 1 | Not reported | Not reported | Not reported | Not reported |
| Synovial Sarcoma Group | 0 | Not reported | Not reported | Not reported | Not reported |
| Osteosarcoma Group | 0 | Not reported | Not reported | Not reported | Not reported |
| Other Sarcomas Group | 0 | Not reported | Not reported | Not reported | Not reported |
| Alveolar Soft-part Sarcoma Group | 4 | Not reported | Not reported | Not reported | Not reported |
| Chordomas Group | 1 | Not reported | Not reported | Not reported | Not reported |
Best Response iRecist - SD
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Adipocytic Tumors Group | 3 | Not reported | Not reported | Not reported | Not reported |
| Vascular Tumors Group | 1 | Not reported | Not reported | Not reported | Not reported |
| Undifferentiated Pleomorphic Sarcoma Group | 1 | Not reported | Not reported | Not reported | Not reported |
| Synovial Sarcoma Group | 3 | Not reported | Not reported | Not reported | Not reported |
| Osteosarcoma Group | 1 | Not reported | Not reported | Not reported | Not reported |
| Other Sarcomas Group | 3 | Not reported | Not reported | Not reported | Not reported |
| Alveolar Soft-part Sarcoma Group | 5 | Not reported | Not reported | Not reported | Not reported |
| Chordomas Group | 3 | Not reported | Not reported | Not reported | Not reported |
Best Response iRecist - uPD
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Adipocytic Tumors Group | 0 | Not reported | Not reported | Not reported | Not reported |
| Vascular Tumors Group | 1 | Not reported | Not reported | Not reported | Not reported |
| Undifferentiated Pleomorphic Sarcoma Group | 1 | Not reported | Not reported | Not reported | Not reported |
| Synovial Sarcoma Group | 2 | Not reported | Not reported | Not reported | Not reported |
| Osteosarcoma Group | 0 | Not reported | Not reported | Not reported | Not reported |
| Other Sarcomas Group | 3 | Not reported | Not reported | Not reported | Not reported |
| Alveolar Soft-part Sarcoma Group | 0 | Not reported | Not reported | Not reported | Not reported |
| Chordomas Group | 0 | Not reported | Not reported | Not reported | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- value
- 0
- group Id
- OG001
- value
- 0
- group Id
- OG002
- value
- 0
- group Id
- OG003
- value
- 0
- group Id
- OG004
- value
- 1
- group Id
- OG005
- value
- 0
- group Id
- OG006
- value
- 0
- group Id
- OG007
- value
- 0
- title
- Best Response irRC - N/A
- categories
- measurements
- group Id
- OG000
- value
- 3
- group Id
- OG001
- value
- 7
- group Id
- OG002
- value
- 2
- group Id
- OG003
- value
- 1
- group Id
- OG004
- value
- 3
- group Id
- OG005
- value
- 5
- group Id
- OG006
- value
- 1
- group Id
- OG007
- value
- 1
- title
- Best Response irRC - PD
- categories
- measurements
- group Id
- OG000
- value
- 0
- group Id
- OG001
- value
- 1
- group Id
- OG002
- value
- 1
- group Id
- OG003
- value
- 0
- group Id
- OG004
- value
- 0
- group Id
- OG005
- value
- 0
- group Id
- OG006
- value
- 5
- group Id
- OG007
- value
- 1
- title
- Best Response irRC - PR
- categories
- measurements
- group Id
- OG000
- value
- 3
- group Id
- OG001
- value
- 1
- group Id
- OG002
- value
- 1
- group Id
- OG003
- value
- 2
- group Id
- OG004
- value
- 1
- group Id
- OG005
- value
- 3
- group Id
- OG006
- value
- 4
- group Id
- OG007
- value
- 3
- title
- Best Response irRC - SD
- categories
- measurements
- group Id
- OG000
- value
- 0
- group Id
- OG001
- value
- 1
- group Id
- OG002
- value
- 1
- group Id
- OG003
- value
- 2
- group Id
- OG004
- value
- 0
- group Id
- OG005
- value
- 3
- group Id
- OG006
- value
- 0
- group Id
- OG007
- value
- 0
- title
- Best Response irRC - uPD
- categories
- measurements
- group Id
- OG000
- value
- 0
- group Id
- OG001
- value
- 0
- group Id
- OG002
- value
- 0
- group Id
- OG003
- value
- 0
- group Id
- OG004
- value
- 1
- group Id
- OG005
- value
- 0
- group Id
- OG006
- value
- 0
- group Id
- OG007
- value
- 0
- title
- Best Response iRecist - N/A
- categories
- measurements
- group Id
- OG000
- value
- 3
- group Id
- OG001
- value
- 7
- group Id
- OG002
- value
- 2
- group Id
- OG003
- value
- 0
- group Id
- OG004
- value
- 3
- group Id
- OG005
- value
- 5
- group Id
- OG006
- value
- 1
- group Id
- OG007
- value
- 1
- title
- Best Response iRecist - PD
- categories
- measurements
- group Id
- OG000
- value
- 0
- group Id
- OG001
- value
- 1
- group Id
- OG002
- value
- 1
- group Id
- OG003
- value
- 0
- group Id
- OG004
- value
- 0
- group Id
- OG005
- value
- 0
- group Id
- OG006
- value
- 4
- group Id
- OG007
- value
- 1
- title
- Best Response iRecist - PR
- categories
- measurements
- group Id
- OG000
- value
- 3
- group Id
- OG001
- value
- 1
- group Id
- OG002
- value
- 1
- group Id
- OG003
- value
- 3
- group Id
- OG004
- value
- 1
- group Id
- OG005
- value
- 3
- group Id
- OG006
- value
- 5
- group Id
- OG007
- value
- 3
- title
- Best Response iRecist - SD
- categories
- measurements
- group Id
- OG000
- value
- 0
- group Id
- OG001
- value
- 1
- group Id
- OG002
- value
- 1
- group Id
- OG003
- value
- 2
- group Id
- OG004
- value
- 0
- group Id
- OG005
- value
- 3
- group Id
- OG006
- value
- 0
- group Id
- OG007
- value
- 0
- title
- Best Response iRecist - uPD
- denoms
- counts
- group Id
- OG000
- value
- 6
- group Id
- OG001
- value
- 10
- group Id
- OG002
- value
- 5
- group Id
- OG003
- value
- 5
- group Id
- OG004
- value
- 5
- group Id
- OG005
- value
- 11
- group Id
- OG006
- value
- 10
- group Id
- OG007
- value
- 5
- units
- Participants
- description
- Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR),Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR
- groups
- description
- Adipocytic Tumors Group consists of well-diff/de-differentiated, pleomorphic and myxoid LPS. Age group ≥12 and \<18: Dosages of study drugs to be determined (TBD). Age group ≥ 18: Durvalumab 1500 mg and Tremelimumab 75 mg every 4 weeks for 4 cycles followed by durvalumab 1500 mg every 4 weeks for up to 8 additional cycles. Combination of both agents administered every 4 weeks for a maximum of 4 doses, after which durvalumab continues as a single agent every 4 weeks till progression or unacceptable toxicity for a maximum of 8 additional doses. Durvalumab: Age group ≥ 18: Durvalumab 1500 mg by vein every 4 weeks for 4 cycles. After Week 16, participant may continue to receive durvalumab alone by vein for an additional 32 weeks (8 doses). Tremelimumab: Age group ≥ 18: Tremelimumab 75 mg every 4 weeks for 4 cycles.
- id
- OG000
- title
- Adipocytic Tumors Group
- description
- Vascular Tumors Group consists of leiomyosarcomas, angiosarcomas, epithelioid hemangioendotheliomas, and hemangiopericytomas. Age group ≥12 and \<18: Dosages of study drugs to be determined (TBD). Age group ≥ 18: Durvalumab1500 mg and Tremelimumab 75 mg every 4 weeks for 4 cycles followed by Durvalumab 1500 mg every 4 weeks for up to 8 additional cycles. Combination of both agents administered every 4 weeks for a maximum of 4 doses, after which durvalumab continues as a single agent every 4 weeks till progression or unacceptable toxicity for a maximum of 8 additional doses. Durvalumab: Age group ≥ 18: Durvalumab 1500 mg by vein every 4 weeks for 4 cycles. After Week 16, participant may continue to receive durvalumab alone by vein for an additional 32 weeks (8 doses). Tremelimumab: Age group ≥ 18: Tremelimumab 75 mg every 4 weeks for 4 cycles.
- id
- OG001
- title
- Vascular Tumors Group
- description
- Age group ≥12 and \<18: Dosages of study drugs to be determined (TBD). Age group ≥ 18: Durvalumab 1500 mg and Tremelimumab 75 mg every 4 weeks for 4 cycles followed by Durvalumab 1500 mg every 4 weeks for up to 8 additional cycles. Combination of both agents administered every 4 weeks for a maximum of 4 doses, after which durvalumab continues as a single agent every 4 weeks till progression or unacceptable toxicity for a maximum of 8 additional doses. Durvalumab: Age group ≥ 18: Durvalumab 1500 mg by vein every 4 weeks for 4 cycles. After Week 16, participant may continue to receive durvalumab alone by vein for an additional 32 weeks (8 doses). Tremelimumab: Age group ≥ 18: Tremelimumab 75 mg every 4 weeks for 4 cycles.
- id
- OG002
- title
- Undifferentiated Pleomorphic Sarcoma Group
- description
- Age group ≥12 and \<18: Dosages of study drugs to be determined (TBD). Age group ≥ 18: Durvalumab 1500 mg and Tremelimumab 75 mg every 4 weeks for 4 cycles followed by durvalumab 1500 mg every 4 weeks for up to 8 additional cycles. Combination of both agents administered every 4 weeks for a maximum of 4 doses, after which Durvalumab continues as a single agent every 4 weeks till progression or unacceptable toxicity for a maximum of 8 additional doses. Durvalumab: Age group ≥ 18: Durvalumab 1500 mg by vein every 4 weeks for 4 cycles. After Week 16, participant may continue to receive durvalumab alone by vein for an additional 32 weeks (8 doses). Tremelimumab: Age group ≥ 18: Tremelimumab 75 mg every 4 weeks for 4 cycles.
- id
- OG003
- title
- Synovial Sarcoma Group
- description
- Age group ≥12 and \<18: Dosages of study drugs to be determined (TBD). Age group ≥ 18: Durvalumab 1500 mg and Tremelimumab 75 mg every 4 weeks for 4 cycles followed by durvalumab 1500 mg every 4 weeks for up to 8 additional cycles. Combination of both agents administered every 4 weeks for a maximum of 4 doses, after which Durvalumab continues as a single agent every 4 weeks till progression or unacceptable toxicity for a maximum of 8 additional doses. Durvalumab: Age group ≥ 18: Durvalumab 1500 mg by vein every 4 weeks for 4 cycles. After Week 16, participant may continue to receive durvalumab alone by vein for an additional 32 weeks (8 doses). Tremelimumab: Age group ≥ 18: Tremelimumab 75 mg every 4 weeks for 4 cycles.
- id
- OG004
- title
- Osteosarcoma Group
- description
- Age group ≥12 and \<18: Dosages of study drugs to be determined (TBD). Age group ≥ 18: Durvalumab 1500 mg and Tremelimumab 75 mg every 4 weeks for 4 cycles followed by durvalumab 1500 mg every 4 weeks for up to 8 additional cycles. Combination of both agents administered every 4 weeks for a maximum of 4 doses, after which Durvalumab continues as a single agent every 4 weeks till progression or unacceptable toxicity for a maximum of 8 additional doses. Durvalumab: Age group ≥ 18: Durvalumab 1500 mg by vein every 4 weeks for 4 cycles. After Week 16, participant may continue to receive durvalumab alone by vein for an additional 32 weeks (8 doses). Tremelimumab: Age group ≥ 18: Tremelimumab 75 mg every 4 weeks for 4 cycles.
- id
- OG005
- title
- Other Sarcomas Group
- description
- Age group ≥12 and \<18: Dosages of study drugs to be determined (TBD). Age group ≥ 18: Durvalumab 1500 mg and Tremelimumab 75 mg every 4 weeks for 4 cycles followed by durvalumab 1500 mg every 4 weeks for up to 8 additional cycles. Combination of both agents administered every 4 weeks for a maximum of 4 doses, after which Durvalumab continues as a single agent every 4 weeks till progression or unacceptable toxicity for a maximum of 8 additional doses. Durvalumab: Age group ≥ 18: Durvalumab 1500 mg by vein every 4 weeks for 4 cycles. After Week 16, participant may continue to receive durvalumab alone by vein for an additional 32 weeks (8 doses). Tremelimumab: Age group ≥ 18: Tremelimumab 75 mg every 4 weeks for 4 cycles.
- id
- OG006
- title
- Alveolar Soft-part Sarcoma Group
- description
- Age group ≥12 and \<18: Dosages of study drugs to be determined (TBD). Age group ≥ 18: Durvalumab 1500 mg and Tremelimumab 75 mg every 4 weeks for 4 cycles followed by durvalumab 1500 mg every 4 weeks for up to 8 additional cycles. Combination of both agents administered every 4 weeks for a maximum of 4 doses, after which Durvalumab continues as a single agent every 4 weeks till progression or unacceptable toxicity for a maximum of 8 additional doses. Durvalumab: Age group ≥ 18: Durvalumab 1500 mg by vein every 4 weeks for 4 cycles. After Week 16, participant may continue to receive durvalumab alone by vein for an additional 32 weeks (8 doses). Tremelimumab: Age group ≥ 18: Tremelimumab 75 mg every 4 weeks for 4 cycles.
- id
- OG007
- title
- Chordomas Group
- param Type
- COUNT_OF_PARTICIPANTS
- reporting Status
- POSTED
- time Frame
- 8 weeks, confirmatory scan at least 4 wks or later
- title
- Tumor Response
- type
- SECONDARY
- unit Of Measure
- Participants
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice